TL;DR
Estrogen receptor-positive (ER+) breast cancer cells can lie dormant for years after treatment, leading to late recurrences. This study reveals that epithelial-mesenchymal plasticity (EMP) is key to ER+ cancer cell dormancy, and restoring epithelial characteristics can reawaken these dormant cells, offering a potential therapeutic target.
What Problem Does This Paper Address?
A significant clinical challenge in treating ER+ breast cancer is its tendency to recur decades after initial therapy. The mechanisms behind this "dormancy" and late recurrence are poorly understood, partly due to a lack of suitable animal models that accurately mimic human disease progression. Existing models often fail to capture the specific behaviors of ER+ disseminated tumor cells (DTCs) in a clinically relevant manner. This paper aims to address this gap by developing and utilizing a novel intraductal xenograft model to investigate ER+ breast cancer dormancy and its underlying mechanisms.
Methods
The researchers employed a sophisticated intraductal xenograft model in immunocompromised mice (MIND models). This approach involves injecting human breast cancer cell lines or patient-derived xenografts (PDXs) directly into the milk ducts of the mammary gland, which better mimics the natural progression of breast cancer compared to subcutaneous injections.
Key techniques and analyses included:
- Bioluminescence imaging: Used to track tumor growth and dissemination of cancer cells in vivo.
- Fluorescence stereomicroscopy and immunohistochemistry (IHC): To visualize and characterize disseminated tumor cells (DTCs) in various organs and assess their morphology and protein expression.
- Cell cycle analysis (FUCCI reporter): To determine the proliferative status of DTCs.
- Gene expression analysis (RT-PCR, microdissection): To quantify the expression of genes associated with epithelial-mesenchymal plasticity (EMP), dormancy, and proliferation.
- RNA velocity analysis: A cutting-edge technique to infer the dynamic changes in gene expression and predict cell state transitions.
- Genetic manipulation: Downregulation of E-cadherin (CDH1) and overexpression of EMP-related transcription factors (like ZEB1) to induce EMP, and overexpression of E-cadherin to revert cells to an epithelial state.
- Single-cell RNA sequencing (scRNA-seq): To comprehensively analyze the heterogeneity of primary tumor cells and DTCs and identify distinct cell populations.
Datasets
The study utilized several human breast cancer cell lines (MCF-7, T47D, BT20, HCC1806) and patient-derived xenografts (PDXs) representing both ER+ and triple-negative (TN) subtypes. These were used to establish the intraductal xenograft models.
The scRNA-seq data generated from primary tumor cells and lung DTCs of MCF-7 xenografts was deposited in the Gene Expression Omnibus (GEO) database under accession code GSE196936.
Key Insights and Ideas
- EMP is the hallmark of ER+ dormancy: Unlike triple-negative breast cancer (TNBC) DTCs, which remain proliferative, ER+ DTCs enter a dormant state characterized by epithelial-mesenchymal plasticity (EMP). This involves a shift towards a more mesenchymal phenotype, with decreased E-cadherin and increased expression of EMT transcription factors like ZEB1.
- Dormancy is a reversible state: The study demonstrates that forcing ER+ DTCs to reacquire epithelial characteristics, specifically by restoring E-cadherin expression, can overcome dormancy and reinitiate proliferation. This suggests that the mesenchymal state is crucial for maintaining dormancy.
- Microenvironment plays a role in awakening: Cytokine signaling, particularly IL-6-induced STAT3 activation, appears to be a key trigger for awakening dormant DTCs. This signaling can directly influence the expression of genes like E-cadherin, promoting a transition back to an epithelial state.
- Intraductal xenografts are powerful models: The MIND model effectively recapitulates key aspects of ER+ breast cancer progression, including dormancy and late recurrence, making it a valuable tool for studying these phenomena.
- ESR1 mutations alone are not sufficient for awakening: While ESR1 mutations are common in recurrent ER+ breast cancer, they did not, in this model, directly cause dormant DTCs to reawaken. This suggests other mechanisms are at play.
Key Results
- ER+ DTCs in the lungs exhibited significantly reduced proliferation (lower Ki67 index) and a higher proportion of cells in the G0/G1 phase compared to primary tumors.
- ER+ DTCs showed a mesenchymal morphology and increased expression of EMP markers (ZEB1, ZEB2, VIM) and decreased expression of epithelial markers (CDH1).
- Forced expression of E-cadherin in ER+ DTCs (MCF-7 cells) led to reacquisition of an epithelial state, increased proliferation, and a significant increase in lung micro-metastasis.
- Genetic manipulation to induce EMP (CDH1 knockdown or ZEB1 overexpression) in ER+ cells did not increase primary tumor growth or metastatic propensity, suggesting that EMP is primarily a mechanism for dormancy rather than invasion in this context.
- Single-cell RNA sequencing revealed distinct populations of DTCs, with "inactive" clusters showing EMT signatures and "active" clusters exhibiting proliferative and epithelial markers.
Limitations and Future Work
- Immune system absence: The MIND models utilize immunocompromised mice, which limits the study of how the immune system might influence DTC dormancy and awakening. Future work could involve restoring a functional human immune system.
- In vitro vs. in vivo plasticity: RNA velocity analysis, while powerful, primarily predicts short-term cell state transitions. Further studies are needed to fully understand the long-term in vivo plasticity of DTCs.
- Barcoding experiments: To definitively distinguish between primary tumor cells and DTCs that may have undergone EMP, barcoding experiments are suggested.
- Therapeutic targeting: The findings suggest that targeting the exit from EMP or the signaling pathways that promote awakening (like IL-6/STAT3) could be promising therapeutic strategies for preventing late recurrence in ER+ breast cancer. The study also hints that CDK4 inhibitors might play a role by blocking exit from dormancy.
Summary updated